Tinzaparin

LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention

STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis

TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer

Effect of Tinzaparin on Inflammatory Biomarkers During the Acute Phase of Deep Vein Thrombosis

Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome

Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID)

Intensive Dose Tinzaparin in Hospitalized COVID-19 Patients

Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer

Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)

A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism

Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses

The STOP CLOT Pilot Study: Study of Low Molecular Weight Heparin in High Risk Cesarean Section

Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer

Use of Tinzaparin for Anticoagulation in Hemodialysis

Can Low Molecular Weight Heparin During Pregnancy With Intrauterine Growth Restriction Increase Birth Weight?

Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure

MesoHep II: Intraperitoneal Low Molecular Weight Heparin in Peritoneal Dialysis

Thromboprophylaxis for Patients Undergoing Surgical Resection for Colon Cancer

Safety and Efficacy of Therapeutic Anticoagulation With Tinzaparin During Pregnancy Via Weight-based Dosing

Venous Thromboembolism Prophylaxis Post Cesarean Section